Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Artificial Vital Organs and Bionics Market $55.5 Billion by 2027

The global market for artificial vital organs and medical bionics to reach $55.5 billion by 2027, expanding at a CAGR of 6.8% over the forecast period, driven by rising organ failure cases and increasing rate of organ transplantation procedures.

  • Some of the main factors fueling the market growth include ageing population, increasing success rate in organ transplantation, scarcity of organ donors, and expanding waiting lists for organ transplantation.
Global Artificial Vital Organs and Bionics Market

The artificial vital organs are devices implanted or integrated into a human body in order to replace a natural organ, for the purpose of duplicating or augmenting a specific function or a group of related functions for the patient to return to a normal life as soon as possible. 

  • On the other hand, medical bionics is the application of biological methods and systems found in nature to the study and design of engineering systems and modern technology. 
    • Medical bionics field is rapidly expanding, with new engineering solutions being developed at an astonishing rate.
Artificial Vital Organs and Medical Bionics Market

With increasing numbers of patients suffering from late stage diseases, organ failure has been responsible for the major part of medical spending.

  • In addition, the rising success rate of transplantation has been encouraging organ failure patients to opt for artificial organs.
    • This in turn has increased the list of patients on the transplant list and the artificial organs market is expected to establish high growth rates over the years.
  • Even though a few of these implantable devices have been approved for clinical use, several other devices are still in the clinical trial phase and are awaiting approval.
    • The FDA and other regulatory bodies across the world have now started increasing the number of product approvals for artificial organ transplantation.

The successful application of these emerging technologies requires a multidisciplinary research environment in order to deliver clinical solutions that are both safe and effective. Bionics involves use of electronics and mechanics incorporated within living beings for the replacement or augmentation of organs and body parts.

  • The key component in developing successful medical bionic solutions is a good understanding of the technological developments in the many enabling technologies that contribute to this field.
    • Some of the clinical success stories include spinal cord stimulation for the management of chronic neurological pain, cochlear implants that allow the profoundly deaf to hear and deep brain stimulation to negate movement disorders in Parkinson’s disease and essential tremor.
  • Other research programs undergoing clinical trials include devices that allow spinal cord injured patients to grasp objects, brain-machine interfaces that allow patients with severe spinal cord injuries to control an artificial limb, devices that detect and suppress epileptic seizures using brief trains of electrical stimulation and vestibular prostheses designed to minimize the debilitating effects of severe balance disorders.

The global artificial vital organs and medical bionics market report provides market size ($million 2017 to 2027), market share, growth trends and forecast (CAGR%, 2021 to 2027). 

The global market for artificial vital organs and medical bionics segmented by product [artificial vital organs – artificial heart (total artificial heart), artificial kidney (hemodialysis machines), artificial liver, artificial pancreas (insulin pumps), artificial lungs (heart-lung bypass machines, oxygenators)]; medical bionics [ear bionics, vision bionics, exoskeletons, bionic limbs (bionic leg, bionic hand), brain bionics (spinal cord stimulators, deep brain stimulators, vagus nerve stimulators), cardiac bionics (ventricular assist device – left ventricular assist device, right ventricular assist device, heart valves – mechanical heart valves, biological tissue valves, transcatheter heart valves)], and geography.

  • In terms of products, the artificial organs segment accounted for the largest share of the total market, whereas the medical bionics segment expected to grow at double-digit rate during the forecast period.
  • Based on artificial organs segment, the artificial kidneys sub-segment leading the global artificial organs market. 
    • The artificial wearable kidneys available in the market are designed for temporary use for up to three days and are battery-powered, providing patient freedom by avoiding conventional dialysis treatment with longer hospital stays and use of bulky, and expensive equipment.
      • This trend is mainly observed in the United States and Europe where, due to the increasing prevalence of renal failure, there is a growing need for dialysis.
  • The artificial pancreas market is expected to see significant growth over the coming years.
    • According to the International Diabetes Federation (IDF), it is expected that by 2030, approximately 550 million people will be affected by diabetes globally.
    • Insulin pumps sub-segment is driven mainly by the increasing incidence of diabetes, better reimbursement policies, high efficacy of these devices and better patient outcomes
      • Advancements in bio-engineering technology are expected to develop an implantable artificial pancreas. This in turn is expected to fuel exponential growth, as more than 100 million people suffer from diabetes mellitus. 

The global artificial vital organs and medical bionics market research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.

  • Geographically, the North America region dominated the global market, followed by Europe.
    • Factors such as increasing number of new product approvals with better biocompatibility, safety and durability features, and subsequent higher rate of artificial organ transplantation procedures are boosting the market in developed countries.
  • However, the Asia Pacific market anticipated to register the fastest double-digit growth rate in the near future.
    • Growing population base in developing countries, rising healthcare awareness and disposable income levels, increasing healthcare expenditure, better patient rehabilitation, growth in medical tourism are propelling the market growth in emerging economies.

The global artificial vital organs and medical bionics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major competitors operating in the global market for artificial vital organs and medical bionics and profiled in this report include Abbott Diabetes Care, Inc., Abiomed, Inc., Asahi Kasei Medical Co., Ltd., Baxter International, Inc., Cyberonics, Inc., Edwards Lifesciences Corporation, Ekso Bionics, F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Gambro AB, Iwalk, Inc., Jarvik Heart, Inc., Medtronic, Inc., Micromed Cardiovascular, Inc., Nikkiso Co., Ltd., Ossur Hf, Ottobock Healthcare Gmbh, Second Sight Medical Products, Inc., Syncardia Systems, Inc., Thoratec Corporation, Touch Bionics, Inc., Vital Therapies, Inc., and Worldheart Corporation.

  • Product 
    • Artificial Vital Organs
      • Artificial Heart
        • Total Artificial Heart (TAH)
      • Artificial Kidney
        • Hemodialysis Machines
      • Artificial Liver
      • Artificial Pancreas
        • Insulin Pumps
      • Artificial Lungs
        • Heart-Lung Bypass Machines
        • Oxygenators
    • Medical Bionics
      • Ear Bionics (Cochlear Implants)
      • Vision Bionics
      • Exoskeletons
      • Bionic Limbs
        • Bionic Leg
        • Bionic Hand
      • Brain Bionics
        • Spinal Cord Stimulators
        • Deep Brain Stimulators
        • Vagus Nerve Stimulators
      • Cardiac Bionics
        • Ventricular Assist Device (VAD)
          • Left Ventricular Assist Device (LVAD)
          • Right Ventricular Assist Device (RVAD)
        • Heart Valves
          • Mechanical Heart Valves
          • Biological Tissue Valves
          • Transcatheter Heart Valves
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Abbott Diabetes Care, Inc.
    • Abiomed, Inc.
    • Asahi Kasei Medical Co., Ltd.
    • Baxter International, Inc.
    • Cyberonics, Inc.
    • Edwards Lifesciences Corporation
    • Ekso Bionics
    • F. Hoffmann-La Roche Ltd.
    • Fresenius Medical Care AG & Co. KGaA
    • Gambro AB
    • Iwalk, Inc.
    • Jarvik Heart, Inc.
    • Medtronic, Inc.
    • Micromed Cardiovascular, Inc.
    • Nikkiso Co., Ltd.
    • Ossur Hf
    • Ottobock Healthcare Gmbh
    • Second Sight Medical Products, Inc.
    • Syncardia Systems, Inc.
    • Thoratec Corporation
    • Touch Bionics, Inc.
    • Vital Therapies, Inc.
    • Worldheart Corporation

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 463-5840
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]